• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上尿路尿路上皮癌中程序性死亡蛋白 1 配体 1 表达升高与肿瘤进展相关,且与肿瘤浸润淋巴细胞密度增加相关。

Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.

机构信息

Department of Urology, Dokkyo Medical University, 880 Kitakobayashi Mibu, Utsunomiya, Tochigi, 321-0293, Japan.

Department of Urology, Utsunomiya Memorial Hospital, Utsunomiya, Tochigi, Japan.

出版信息

Cancer Immunol Immunother. 2020 May;69(5):689-702. doi: 10.1007/s00262-020-02499-7. Epub 2020 Feb 6.

DOI:10.1007/s00262-020-02499-7
PMID:32030476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7183489/
Abstract

BACKGROUND

Increased expression of programmed cell death 1 ligand 1 (PD-L1) by tumor cells is thought to be a mechanism through which solid cancers promote immune tolerance. However, the association between PD-L1 expression and the prognosis of upper urinary tract urothelial carcinoma (UTUC) remains unknown.

METHODS

We examined immunohistochemical PD-L1 expression and the tumor-infiltrating lymphocyte density (TILD) in 79 patients with UTUC who underwent nephroureterectomy. We classified the tumors into four types based on the combination of PD-L1 expression and TILD, and studied the clinicopathological characteristics of these four tumor types.

RESULTS

Elevated expression of PD-L1 by tumor cells and a higher TILD were associated with a worse histological grade, higher pT stage, and higher peripheral blood neutrophil-to-lymphocyte ratio. Elevated expression of PD-L1 by tumor cells, a higher TILD, and type I, III, or IV tumors with elevated expression of either PD-L1 or TILD showed a positive correlation with poorer differentiation and local invasion. These three variables were associated with shorter progression-free survival and overall survival in univariate analysis, but only the latter was an independent determinant according to multivariate analysis. The patients who had type II tumors with lower PD-L1 expression and a lower TILD showed more favorable survival than the other three groups.

CONCLUSIONS

These findings suggest that PD-L1 expression and TILs in the tumor microenvironment influence the progression of UTUC. Accordingly, it is important to understand the immunologic characteristics of the tumor microenvironment to develop more effective treatment strategies for this cancer.

摘要

背景

肿瘤细胞程序性死亡配体 1(PD-L1)的表达增加被认为是实体瘤促进免疫耐受的一种机制。然而,PD-L1 表达与上尿路上皮癌(UTUC)预后之间的关系尚不清楚。

方法

我们对 79 例行肾输尿管切除术的 UTUC 患者的免疫组化 PD-L1 表达和肿瘤浸润淋巴细胞密度(TILD)进行了检测。我们根据 PD-L1 表达和 TILD 的组合将肿瘤分为四种类型,并研究了这四种肿瘤类型的临床病理特征。

结果

肿瘤细胞 PD-L1 表达升高和 TILD 升高与组织学分级较高、pT 分期较高和外周血中性粒细胞与淋巴细胞比值较高相关。肿瘤细胞 PD-L1 表达升高、TILD 升高以及Ⅰ型、Ⅲ型或Ⅳ型肿瘤(PD-L1 或 TILD 表达升高)与分化不良和局部侵犯呈正相关。这些三个变量在单因素分析中与无进展生存期和总生存期较短相关,但只有后者在多因素分析中是独立的决定因素。PD-L1 表达较低且 TILD 较低的Ⅱ型肿瘤患者的生存情况优于其他三组。

结论

这些发现表明 PD-L1 表达和肿瘤微环境中的 TIL 影响 UTUC 的进展。因此,了解肿瘤微环境的免疫特征对于开发这种癌症的更有效治疗策略很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/87e6b83bfcd1/262_2020_2499_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/62c2bec83df7/262_2020_2499_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/f7e553cc4775/262_2020_2499_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/87e6b83bfcd1/262_2020_2499_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/62c2bec83df7/262_2020_2499_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/f7e553cc4775/262_2020_2499_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcf/11027817/87e6b83bfcd1/262_2020_2499_Fig3_HTML.jpg

相似文献

1
Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.上尿路尿路上皮癌中程序性死亡蛋白 1 配体 1 表达升高与肿瘤进展相关,且与肿瘤浸润淋巴细胞密度增加相关。
Cancer Immunol Immunother. 2020 May;69(5):689-702. doi: 10.1007/s00262-020-02499-7. Epub 2020 Feb 6.
2
Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.PD-1 和 PD-L1 表达在高级别上尿路尿路上皮癌患者中的预后价值。
J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.
3
Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.雄激素受体和 PD-L1 在尿路上皮癌中的表达及相关性研究。
Cancer Genomics Proteomics. 2024 Mar-Apr;21(2):137-143. doi: 10.21873/cgp.20435.
4
Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.程序性死亡配体 1 在尿路上皮癌中的表达。
Eur Urol Focus. 2017 Oct;3(4-5):502-509. doi: 10.1016/j.euf.2016.11.011. Epub 2016 Dec 13.
5
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.程序性死亡配体-1 与肿瘤浸润淋巴细胞相关,并与膀胱癌的生存状况较差相关。
Cancer Sci. 2019 Feb;110(2):489-498. doi: 10.1111/cas.13887. Epub 2018 Dec 12.
6
Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.基于 PD-L1/PD-1/CD8 轴的分类器的开发和验证,用于预测根治性肾输尿管切除术治疗上尿路上皮癌的患者的癌症生存情况。
Cancer Immunol Immunother. 2021 Sep;70(9):2657-2668. doi: 10.1007/s00262-020-02827-x. Epub 2021 Feb 19.
7
Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.PD-L1在上尿路上皮癌肿瘤细胞和肿瘤浸润单核细胞上的表达的预后意义。
Med Oncol. 2017 May;34(5):94. doi: 10.1007/s12032-017-0941-2. Epub 2017 Apr 13.
8
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.肿瘤细胞 PD-L1 高表达与预后不良相关,而免疫细胞 PD-L1 高表达则是膀胱癌的一个有利预后因素。
Future Oncol. 2021 Aug;17(22):2893-2905. doi: 10.2217/fon-2021-0092. Epub 2021 Jun 30.
9
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.基于 PD-L1 表达和肿瘤浸润淋巴细胞的肺腺癌和鳞状细胞癌免疫微环境景观。
Cancer Med. 2019 Dec;8(17):7207-7218. doi: 10.1002/cam4.2580. Epub 2019 Oct 11.
10
PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma.PD-L1 表达与上尿路上皮癌的鳞状分化具有显著相关性。
Am J Clin Pathol. 2019 May 3;151(6):561-573. doi: 10.1093/ajcp/aqz002.

引用本文的文献

1
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.上尿路尿路上皮癌:当前治疗方案中的独特免疫-分子实体和临床挑战。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231159753. doi: 10.1177/15330338231159753.
2
Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.在上尿路尿路上皮癌中,基质 HHLA2 和成纤维细胞激活蛋白的共表达增加。
Int Urol Nephrol. 2023 Apr;55(4):867-874. doi: 10.1007/s11255-022-03458-0. Epub 2023 Jan 4.
3
Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells.

本文引用的文献

1
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.程序性死亡配体-1 与肿瘤浸润淋巴细胞相关,并与膀胱癌的生存状况较差相关。
Cancer Sci. 2019 Feb;110(2):489-498. doi: 10.1111/cas.13887. Epub 2018 Dec 12.
2
Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.肿瘤浸润淋巴细胞对接受铂类化疗的转移性尿路上皮癌患者预后的影响。
Sci Rep. 2018 May 10;8(1):7485. doi: 10.1038/s41598-018-25944-1.
3
Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.
肿瘤芽生是胰腺腺癌的一个独立预后因素,且它与肿瘤细胞上的PD-L1表达呈正相关。
Biomedicines. 2022 Jul 21;10(7):1761. doi: 10.3390/biomedicines10071761.
4
Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma. stromal periostin 表达在上尿路尿路上皮癌中的预后影响。
BMC Cancer. 2022 Jul 18;22(1):787. doi: 10.1186/s12885-022-09893-7.
5
Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients.癌症免疫组织化学图谱通过免疫组织化学代表癌症-免疫周期,可预测免疫检查点抑制剂在泌尿系统癌症患者中的疗效。
Sci Rep. 2022 Jun 23;12(1):10617. doi: 10.1038/s41598-022-14700-1.
6
Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.喉癌和下咽鳞状细胞癌中免疫细胞浸润及中性粒细胞与淋巴细胞比值与化疗反应和预后的关系
Cancers (Basel). 2021 Apr 25;13(9):2079. doi: 10.3390/cancers13092079.
7
Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study).基质肿瘤浸润淋巴细胞在局部晚期上尿路尿路上皮癌中的预后作用:一项回顾性多中心研究(TSU-02研究)
Oncoimmunology. 2021 Jan 4;10(1):1861737. doi: 10.1080/2162402X.2020.1861737.
8
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.转移性肾细胞癌中腺苷 2A 受体的表达增加与对血管内皮生长因子抑制剂和抗 PD-1/抗 CTLA4 抗体的反应较差以及生存时间较短相关。
Cancer Immunol Immunother. 2021 Jul;70(7):2009-2021. doi: 10.1007/s00262-020-02843-x. Epub 2021 Jan 8.
9
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.PD-L1在上尿路尿路上皮癌患者接受根治性肾输尿管切除术中的患病率及预后作用:一项系统评价和荟萃分析
Front Oncol. 2020 Aug 21;10:1400. doi: 10.3389/fonc.2020.01400. eCollection 2020.
中性粒细胞与淋巴细胞比值在上尿路尿路上皮癌中是否为临床相关的术前生物标志物?一项 4385 例患者的荟萃分析。
World J Urol. 2018 Jul;36(7):1019-1029. doi: 10.1007/s00345-018-2235-5. Epub 2018 Feb 21.
4
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.宿主表达 PD-L1 决定 PD-L1 通路阻断介导的肿瘤消退疗效。
J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16.
5
High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.高 PDL1 mRNA 表达预示着 pT1 期非肌肉浸润性膀胱癌(NMIBC)患者的生存更好。
Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.
6
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.具有不同代谢特征及KDM6A突变频率存在女性性别偏向的非侵袭性膀胱癌的基因组亚型
Cancer Cell. 2017 Nov 13;32(5):701-715.e7. doi: 10.1016/j.ccell.2017.08.005.
7
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
8
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2017 年更新版。
Eur Urol. 2018 Jan;73(1):111-122. doi: 10.1016/j.eururo.2017.07.036. Epub 2017 Sep 1.
9
Neutrophils in cancer: prognostic role and therapeutic strategies.中性粒细胞与癌症:预后作用和治疗策略。
Mol Cancer. 2017 Aug 15;16(1):137. doi: 10.1186/s12943-017-0707-7.
10
Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.程序性死亡配体 1 在尿路上皮癌中的表达。
Eur Urol Focus. 2017 Oct;3(4-5):502-509. doi: 10.1016/j.euf.2016.11.011. Epub 2016 Dec 13.